Case Reports in Oncology最新文献_第6页

Remarkable Response to Cisplatin-Based Chemotherapy and Long-Term Remission in a Young Male with Widespread Extragonadal Choriocarcinoma: A Case Report and Literature Review. 以顺铂为基础的化疗的显著反应和长期缓解在一个广泛的睾丸外绒毛膜癌的年轻男性：一个病例报告和文献复习。

IF 0.7

Case Reports in Oncology Pub Date : 2025-06-12 eCollection Date: 2025-01-01 DOI: 10.1159/000546751

Abdulmajeed Alshabanat, Waad Aldahlawi, Siham Hussein, Wajd Althakfi, Ahmed Ibrahim

{"title":"Remarkable Response to Cisplatin-Based Chemotherapy and Long-Term Remission in a Young Male with Widespread Extragonadal Choriocarcinoma: A Case Report and Literature Review.","authors":"Abdulmajeed Alshabanat, Waad Aldahlawi, Siham Hussein, Wajd Althakfi, Ahmed Ibrahim","doi":"10.1159/000546751","DOIUrl":"10.1159/000546751","url":null,"abstract":"Introduction: Choriocarcinoma is a rare and aggressive germ cell tumor that presents significant diagnostic challenges, particularly in males, where it is typically found in the gonads. Most patients present with advanced disease, often exhibiting symptoms related to metastatic spread, such as shortness of breath, cough, and hemoptysis. The rarity of extragonadal choriocarcinoma and its non-specific presentation make early diagnosis difficult, emphasizing the need for a multidisciplinary approach to treatment.Case presentation: A 31-year-old male presented with progressive shortness of breath, cough, and hemoptysis for over a month. Initial imaging revealed multiple pulmonary nodules and a large necrotic retroperitoneal mass, along with liver metastases. The patient's β-human chorionic gonadotropin (β-hCG) levels were markedly elevated, raising suspicion of choriocarcinoma, subsequently confirmed through biopsy. Given the rapid clinical deterioration, chemotherapy with cisplatin and etoposide was initiated. The patient responded well to treatment, with a significant reduction in tumor and metastasis size. Over 30 months of follow-up, the patient showed continued clinical improvement with no evidence of disease recurrence.Conclusion: Extragonadal choriocarcinoma is a highly aggressive and rare malignancy that poses significant diagnostic and therapeutic challenges. This case underscores the importance of early intervention and the need for ongoing research to improve outcomes in these patients. A multidisciplinary approach is crucial for optimal management.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"949-957"},"PeriodicalIF":0.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review. 高度预处理的复发性卵巢癌患者在发生多系统免疫相关不良事件后延长无进展生存期：一个病例报告和文献综述。

IF 0.7

Case Reports in Oncology Pub Date : 2025-06-11 eCollection Date: 2025-01-01 DOI: 10.1159/000546423

Minling Liu, Shuo Fang, Huiru Dai, Tingwei Li, Chunyan Guo, Bo Wang

{"title":"Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review.","authors":"Minling Liu, Shuo Fang, Huiru Dai, Tingwei Li, Chunyan Guo, Bo Wang","doi":"10.1159/000546423","DOIUrl":"10.1159/000546423","url":null,"abstract":"Introduction: The development of immune-related adverse events (irAEs) has been associated with improved survival from various solid tumors. Given that immunotherapy has not been widely used in ovarian cancer and has only been applied to patients with high tumor mutational burden or microsatellite instability, studies exploring the effects of irAEs on ovarian cancer have been limited.Case presentation: A 47-year-old woman was diagnosed with International Federation of Gynecology and Obstetrics stage III ovarian cancer in 2013. Between 2013 and 2021, she underwent palliative chemotherapy comprising paclitaxel liposomes, cisplatin/nedaplatin, S-1/raltitrexed, irinotecan, doxorubicin, vinorebine, toripalimab, apatinib, gemcitabine, oxaliplatin, and capecitabine, as well as two debulking surgeries. From November 2021, she received six cycles of tislelizumab (a PD-1 inhibitor), paclitaxel (albumin-bound), and carboplatin, to which a partial response was observed according to the Response Evaluation Criteria in Solid Tumors. From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib. However, all antitumor treatments were discontinued from April 2023 due to multiple irAEs, including hypothyroidism, adrenal insufficiency, and pneumonitis, with the tumor remaining stable until November 2023. Progression-free survival (PFS) was approximately 24 months with tislelizumab-containing therapy but was 18 months with tislelizumab/olaparib maintenance therapy.Conclusions: We report a case involving a patient with highly pretreated recurrent ovarian cancer who exhibited prolonged PFS after developing three irAEs. The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"912-919"},"PeriodicalIF":0.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12245149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Management of Immune-Mediated Myelitis in a Renal Cancer Patient: A Case Report. 肾癌患者免疫介导性脊髓炎的成功治疗一例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2025-06-11 eCollection Date: 2025-01-01 DOI: 10.1159/000543929

Paula Rodríguez Payá, Álvaro Muñoz Abad, Beatriz Grau Mirete, Asia Ferrández Arias, Miguel Borregón Rivilla, Javier David Benítez Fuentes, Federico J Vázquez Mazón

{"title":"Successful Management of Immune-Mediated Myelitis in a Renal Cancer Patient: A Case Report.","authors":"Paula Rodríguez Payá, Álvaro Muñoz Abad, Beatriz Grau Mirete, Asia Ferrández Arias, Miguel Borregón Rivilla, Javier David Benítez Fuentes, Federico J Vázquez Mazón","doi":"10.1159/000543929","DOIUrl":"10.1159/000543929","url":null,"abstract":"Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized metastatic renal cell carcinoma treatment, significantly improving survival outcomes. However, ICIs are linked to immune-related adverse events (irAEs), which can impact multiple organs. Neurological irAEs, such as myelitis, are rare but potentially severe.Case presentation: We describe a 54-year-old male with high-grade clear cell renal carcinoma treated with nivolumab and ipilimumab. After four cycles, he developed hypophysitis, adrenal insufficiency, and hypothyroidism, managed with hydrocortisone and levothyroxine, while continuing nivolumab monotherapy. In August 2022, he experienced right eyelid ptosis and right hand weakness. Cranial magnetic resonance imaging (MRI) showed improvement in the sellar lesion, and chronic sensorimotor polyneuropathy was diagnosed, ruling out myasthenia gravis. Nivolumab treatment continued. By December 2022, after seven cycles, the patient developed back pain and dysesthesias, with MRI confirming transverse myelitis from C7 to T3. Nivolumab was discontinued, and high-dose corticosteroids (1 g methylprednisolone daily for 5 days) led to clinical improvement. A 12-week taper followed, with no symptom recurrence. Disease progression in April 2023 led to a switch to pazopanib, maintaining a partial response for 6 months.Conclusion: This case emphasizes the serious nature of neurological irAEs from ICIs and the critical need for early detection and management. It also highlights the increased risk of subsequent irAEs after an initial event, underscoring the importance of vigilant monitoring.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"892-899"},"PeriodicalIF":0.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum. 勘误表。

IF 0.7

Case Reports in Oncology Pub Date : 2025-06-11 eCollection Date: 2025-01-01 DOI: 10.1159/000545845

引用次数: 0

A Super-Aged Patient with Primary Cutaneous Gamma-Delta T-Cell Lymphoma Treated with Palliative Radiotherapy: A Short-Term Follow-Up Case. 姑息性放疗治疗1例原发性皮肤γ - δ t细胞淋巴瘤的高龄患者：一个短期随访病例。

IF 0.7

Case Reports in Oncology Pub Date : 2025-06-07 eCollection Date: 2025-01-01 DOI: 10.1159/000546761

Moyuka Wada-Irimada, Taku Fujimura, Manami Takahashi-Watanabe, Emi Yamazaki, Ryo Amagai, Erika Tamabuchi, Kenta Oka, Yumi Kambayashi, Akira Hashimoto, Toshiya Takahashi, Yoshihide Asano

{"title":"A Super-Aged Patient with Primary Cutaneous Gamma-Delta T-Cell Lymphoma Treated with Palliative Radiotherapy: A Short-Term Follow-Up Case.","authors":"Moyuka Wada-Irimada, Taku Fujimura, Manami Takahashi-Watanabe, Emi Yamazaki, Ryo Amagai, Erika Tamabuchi, Kenta Oka, Yumi Kambayashi, Akira Hashimoto, Toshiya Takahashi, Yoshihide Asano","doi":"10.1159/000546761","DOIUrl":"10.1159/000546761","url":null,"abstract":"Introduction: Primary cutaneous gamma-delta T-cell lymphoma (PCGDTL) is a rare and aggressive subtype of cutaneous T-cell lymphoma, often associated with poor prognosis and resistance to conventional therapies.Case presentation: We present the case of a 91-year-old Japanese man with a 2-month history of rapidly growing, painful nodules on the face, trunk, and extremities. Histopathology showed dermal infiltration by atypical lymphoid cells positive for CD3 and CD5 but negative for cytotoxic markers such as TIA-1 and granzyme B. Flow cytometry confirmed a TCR-γδ+ T-cell phenotype. Given his advanced age, palliative radiotherapy (8 Gy in 4 fractions) was chosen. The treatment was well tolerated and led to dramatic clinical improvement without adverse effects.Conclusion: Although PCGDTL is known for its poor response to both chemotherapy and radiotherapy, this case illustrates the potential of localized radiotherapy as a low-toxicity option that may achieve temporary in selected elderly patients. This report contributes to the limited literature on non-chemotherapy-based management strategies for PCGDTL and highlights the importance of individualized treatment approaches in frail or super-aged patients.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"905-911"},"PeriodicalIF":0.7,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rechallenging Unresectable Hepatocellular Carcinoma with the STRIDE Regimen: A Case Report of Significant AFP Response after Atezolizumab-Bevacizumab Intolerance. 用STRIDE方案重新挑战不可切除的肝细胞癌：阿特唑单抗-贝伐单抗不耐受后显著AFP反应的病例报告

IF 0.7

Case Reports in Oncology Pub Date : 2025-06-07 eCollection Date: 2025-01-01 DOI: 10.1159/000546711

Sugat Adhikari, James Doolin

{"title":"Rechallenging Unresectable Hepatocellular Carcinoma with the STRIDE Regimen: A Case Report of Significant AFP Response after Atezolizumab-Bevacizumab Intolerance.","authors":"Sugat Adhikari, James Doolin","doi":"10.1159/000546711","DOIUrl":"10.1159/000546711","url":null,"abstract":"Introduction: Hepatocellular carcinoma (HCC) is a leading cause of cancer worldwide, with immune checkpoint inhibitors (ICIs) revolutionizing treatment of unresectable HCCs. However, limited data exist on rechallenging patients with alternative ICI regimens, such as STRIDE (durvalumab + tremelimumab), following initial treatment failure or intolerance to atezolizumab + bevacizumab.Case report: A 66-year-old male with advanced cirrhosis, hepatitis C, and a history of alcohol use developed HCC, with an AFP level increasing from 3.4 to 3,199. Imaging revealed a 10.7 cm infiltrative mass with portal vein thrombosis, and the patient was diagnosed with Barcelona Liver Clinic (BCLC) stage C HCC. First-line treatment with atezolizumab + bevacizumab was initiated, but the patient did not tolerate the regimen well, leading to discontinuation. He was switched to the STRIDE regimen, which he tolerated well. After six cycles of durvalumab, significant clinical improvement was noted and a follow-up MRI showed reduced tumor thrombus size, and AFP levels dropped significantly to 2, indicating a sustained or improved therapeutic response.Conclusion: This case suggests that rechallenging with the STRIDE regimen may provide significant clinical benefit in HCC patients intolerant to initial ICI therapy. However, further clinical trials are needed to confirm the efficacy and optimal use of ICI rechallenge strategies in HCC.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"942-948"},"PeriodicalIF":0.7,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aggressive Craniospinal Recurrence of a PTEN-Mutated Sinonasal Teratocarcinosarcoma: A Case Report. pten突变的鼻窦畸形癌肉瘤侵袭性颅脊髓复发1例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2025-06-05 eCollection Date: 2025-01-01 DOI: 10.1159/000546568

Abdel Mun'Em S Al Hourani, Peter H Ahn, Yahia M Tagouri, Timothy Deklotz, Jai Singh Rajput, Ankit Madan

{"title":"Aggressive Craniospinal Recurrence of a PTEN-Mutated Sinonasal Teratocarcinosarcoma: A Case Report.","authors":"Abdel Mun'Em S Al Hourani, Peter H Ahn, Yahia M Tagouri, Timothy Deklotz, Jai Singh Rajput, Ankit Madan","doi":"10.1159/000546568","DOIUrl":"10.1159/000546568","url":null,"abstract":"Introduction: Sinonasal teratocarcinosarcoma (SNTCS) is an aggressive and highly recurrent tumor with a predilection for anterior skull base location. It continues to pose a challenge due to difficulty in diagnosis and the lack of large-scale studies on optimal treatment strategies.Case presentation: We report a case of a 48-year-old female patient who presented with headache, nausea, and vomiting. Initial imaging revealed a 6.4 × 4.5 cm extra-axial mass in the right frontal region, originating from the superior right nasal cavity. She underwent surgical resection of the tumor and was found to have SNTCS. She received concurrent chemoradiotherapy. Next-generation sequencing showed mutations in the PTEN, SMARCA4, and CCND1 genes. Six months after completion of treatment, she experienced an aggressive leptomeningeal recurrence of her disease. To our knowledge, our case represents the first SNTCS case with a documented PTEN mutation. In the absence of evidence-based guidelines due to the rarity of this diagnosis, we have reviewed over 50 cases reported in the literature.Conclusion: SNTCS remains challenging to treat, as despite using surgical resection and concurrent chemoradiotherapy, it continues to have a high recurrence and mortality rate. We further discuss various demographics, chemotherapy regimens, prognosis, and common genetic mutations found in SNTCS.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"935-941"},"PeriodicalIF":0.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concurrent Capillary Hemangioma of Optic Disc and Pituitary Gland Cyst: A Multimodal Imaging Approach and Review of Literature. 视盘并发毛细血管瘤和垂体囊肿：多模态成像方法及文献回顾。

IF 0.7

Case Reports in Oncology Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI: 10.1159/000544876

Devu Krishna Thulaseedharan, Abhishek Das, Parag K Shah, Narendran Venkatapathy

{"title":"Concurrent Capillary Hemangioma of Optic Disc and Pituitary Gland Cyst: A Multimodal Imaging Approach and Review of Literature.","authors":"Devu Krishna Thulaseedharan, Abhishek Das, Parag K Shah, Narendran Venkatapathy","doi":"10.1159/000544876","DOIUrl":"10.1159/000544876","url":null,"abstract":"Introduction: Coexistence of optic disc hemangioma and pituitary gland cyst is a rare clinical scenario. Usually, a retinal capillary hemangioma or juxtapapillary hemangioma is associated with VHL syndrome. This case emphasizes the clinical presentation, diagnostic approach, and implications for patient care.Case presentation: We report a case of a young patient, who came for a routine eye examination and got diagnosed with optic disc hemangioma incidentally. A complete systemic workup was done to rule out VHL syndrome during which MRI brain surprisingly revealed a pituitary gland cyst. The patient was referred to a neurosurgeon and observation was recommended as he was asymptomatic.Conclusion: This case demonstrates how a good clinical examination, prompt documentation, regular follow-ups, and appropriate imaging facilitated the early diagnosis of both the optic disc capillary hemangioma and pituitary gland cyst. Consequently, this report also shows the importance of multimodal imaging in these young patients to detect these potentially life-altering conditions.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"773-779"},"PeriodicalIF":0.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Male Breast Cancer in Rural America: Treatment Delays and Healthcare Access Challenges. 一例男性乳腺癌在美国农村：治疗延误和医疗保健的挑战。

IF 0.7

Case Reports in Oncology Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI: 10.1159/000546042

Siddanth Singh, Hiep Nguyen, Krishna Kapoor, Anh Nguyen, Larry Frase, Madhu Chiluveri

{"title":"A Case of Male Breast Cancer in Rural America: Treatment Delays and Healthcare Access Challenges.","authors":"Siddanth Singh, Hiep Nguyen, Krishna Kapoor, Anh Nguyen, Larry Frase, Madhu Chiluveri","doi":"10.1159/000546042","DOIUrl":"10.1159/000546042","url":null,"abstract":"Introduction: Breast cancer in male is a rare, constituting less than 1% of all breast cancer cases, often leading to delayed diagnoses and poorer outcomes compared to women. Diagnosis in rural settings is particularly challenging due to limited healthcare access, lower awareness, and cultural stigmas. We report a case highlighting the unique challenges faced by rural male breast cancer patients, emphasizing the need for improved screening and awareness.Case presentation: A 60-year-old male with a significant smoking history and breast cancer presented to the emergency department with severe back and left lower extremity pain. Clinical evaluation revealed an erythematous lesion near the left nipple. Imaging and biopsy confirmed worsening metastatic breast carcinoma involving multiple vertebral bodies. The patient previously received hormonal and targeted therapies but discontinued treatment due to lack of resources, insurance issues, and follow-up associated with breast cancer diagnosis. Upon reinitiating treatment and receiving palliative radiation, the patient showed significant clinical improvement, demonstrating a complete metabolic response on follow-up imaging.Conclusion: This case underscores the significant barriers to timely breast cancer diagnosis and management in men, particularly in rural communities. Increased awareness, targeted screening protocols, and improved healthcare access are critical to addressing these disparities, potentially improving prognosis and quality of life for male breast cancer patients.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"885-891"},"PeriodicalIF":0.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12237286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are Poly (ADP-Ribose) Polymerase Inhibitors Safe in Paraneoplastic Dermatomyositis due to High-Grade Serous Carcinoma of the Ovary? A Case Report and a Review of the Literature. 聚（adp -核糖）聚合酶抑制剂治疗卵巢高级别浆液性癌所致的副瘤性皮肌炎安全吗？一例报告及文献回顾。

IF 0.7

Case Reports in Oncology Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI: 10.1159/000546665

Kaneez Koheeallee, Apostolos Sarivalasis

{"title":"Are Poly (ADP-Ribose) Polymerase Inhibitors Safe in Paraneoplastic Dermatomyositis due to High-Grade Serous Carcinoma of the Ovary? A Case Report and a Review of the Literature.","authors":"Kaneez Koheeallee, Apostolos Sarivalasis","doi":"10.1159/000546665","DOIUrl":"10.1159/000546665","url":null,"abstract":"Introduction: Dermatomyositis (DM) is a chronic autoimmune disorder characterized by noninfectious inflammation of the muscles and skin [Curr Treat Options Neurol. 2003;5(5):349-56]. An interesting aspect of DM is its correlation with cancer, particularly as paraneoplastic syndrome, in up to 30% of all cases [Int J Mol Sci. 2020;21(6):2178]. There is a notable association with specific cancers, such as lung cancer in men and breast or ovarian cancer (OC) in women. OC is responsible in up to 13.3%-21.4% of DM cases in women. Thus, it is important to explore whether poly (ADP-ribose) polymerase inhibitors (iPARP), a key component of OC maintenance treatment, are safe to use in patients with paraneoplastic DM especially since iPARP could be associated with an immunomodulatory effect with unknown impact on paraneoplastic syndromes.Case presentation: A 69-year-old patient without significant comorbidities was undergoing dermatological investigations for a persistent skin rash suspect of DM. In her preplanned appointment, bilateral ovarian masses were detected. The skin biopsy confirmed a DM. The DM was associated with an underlying advanced FIGO IIIC high-grade serous ovarian cancer (HGSOC) not amendable to a primary debulking surgery. Following perioperative chemotherapy and a macroscopically complete interval debulking surgery, the patient was to receive iPARP. On immunosuppressive treatment, DM was in near complete remission; thus, the safety of iPARP needed to be reviewed before treatment initiation.Conclusion: This article reports on a case of HGSOC receiving iPARP maintenance following standard of care interval debulking surgery. On this treatment, the patient did not experience DM flair and remains in complete oncological response.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"878-884"},"PeriodicalIF":0.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0